Free Trial Information
BioCentury | Nov 18, 2013
Company News

Savira Pharmaceuticals, Roche deal

...to other ongoing collaborations until 2015, but is likely not to engage in new projects. Savira Pharmaceuticals GmbH...
Read More
BioCentury | Nov 5, 2012
Company News

Savira Pharmaceuticals management update

Savira Pharmaceuticals GmbH , Vienna, Austria Business: Infectious Hired: Andreas Hauer as CFO, formerly a department head in the corporate and investment banking division at Erste Group Bank WIR Staff Infectious...
Read More
BioCentury | Jun 11, 2012
Company News

Savira Pharmaceuticals, Roche deal

...$302.2 million) in milestones, plus royalties. Savira was founded in 2009. Details were not disclosed. Savira Pharmaceuticals GmbH...
Read More
BioCentury | Jun 5, 2012
Company News

Savira, Roche in influenza deal

Savira Pharmaceuticals GmbH (Vienna, Austria) granted Roche (SIX:ROG; OTCQX:RHHBY) exclusive, worldwide rights to its small molecule program targeting the "cap-snatching mechanism" of influenza polymerase. The enzyme uses the mechanism to hijack a piece of host...
Read More
BioCentury | Apr 19, 2012
Distillery Therapeutics

Indication: Infectious disease

...T-705), a viral polymerase inhibitor, is in Phase III testing to treat seasonal influenza virus. Savira Pharmaceuticals GmbH...
Read More
BioCentury | Jul 11, 2011
Emerging Company Profile

Savira: Capping influenza

...Vienna, Austria Savira Pharmaceuticals GmbH , Vienna, Austria Toyama Chemical Co. Ltd. , Tokyo, Japan Sidebars Savira Pharmaceuticals GmbH...
Read More
BioCentury | Oct 5, 2009
Financial News

Savira Pharmaceuticals completes venture financing

Savira Pharmaceuticals GmbH , Vienna, Austria Business: Infectious Date completed: 9/23/09 Type: Venture financing Raised: €1 million ($1.5 million) Investors: Austria Wirtschaftsservice WIR Staff Infectious...
Read More
Items per page:
1 - 7 of 7
BioCentury | Nov 18, 2013
Company News

Savira Pharmaceuticals, Roche deal

...to other ongoing collaborations until 2015, but is likely not to engage in new projects. Savira Pharmaceuticals GmbH...
Read More
BioCentury | Nov 5, 2012
Company News

Savira Pharmaceuticals management update

Savira Pharmaceuticals GmbH , Vienna, Austria Business: Infectious Hired: Andreas Hauer as CFO, formerly a department head in the corporate and investment banking division at Erste Group Bank WIR Staff Infectious...
Read More
BioCentury | Jun 11, 2012
Company News

Savira Pharmaceuticals, Roche deal

...$302.2 million) in milestones, plus royalties. Savira was founded in 2009. Details were not disclosed. Savira Pharmaceuticals GmbH...
Read More
BioCentury | Jun 5, 2012
Company News

Savira, Roche in influenza deal

Savira Pharmaceuticals GmbH (Vienna, Austria) granted Roche (SIX:ROG; OTCQX:RHHBY) exclusive, worldwide rights to its small molecule program targeting the "cap-snatching mechanism" of influenza polymerase. The enzyme uses the mechanism to hijack a piece of host...
Read More
BioCentury | Apr 19, 2012
Distillery Therapeutics

Indication: Infectious disease

...T-705), a viral polymerase inhibitor, is in Phase III testing to treat seasonal influenza virus. Savira Pharmaceuticals GmbH...
Read More
BioCentury | Jul 11, 2011
Emerging Company Profile

Savira: Capping influenza

...Vienna, Austria Savira Pharmaceuticals GmbH , Vienna, Austria Toyama Chemical Co. Ltd. , Tokyo, Japan Sidebars Savira Pharmaceuticals GmbH...
Read More
BioCentury | Oct 5, 2009
Financial News

Savira Pharmaceuticals completes venture financing

Savira Pharmaceuticals GmbH , Vienna, Austria Business: Infectious Date completed: 9/23/09 Type: Venture financing Raised: €1 million ($1.5 million) Investors: Austria Wirtschaftsservice WIR Staff Infectious...
Read More
Items per page:
1 - 7 of 7